Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Beller

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1991
Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridineF M Muggia, K K Chan, C Russell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1990
Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapyJ L Speyer, U Beller, N Colombo, et al.
American Journal of Human Genetics|May 1, 1997
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer familiesE Levy-Lahad, R Catane, S Eisenberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2001
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriersE Levy-Lahad, A Lahad, S Eisenberg, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|July 20, 2000
p53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutationsD Yair, G Ben Baruch, A Chetrit, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 12, 2005
A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancerO Gemer, M Lurian, M Gdalevich, et al.
The New England Journal of Medicine|July 28, 2001
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutationB Modan, P Hartge, G Hirsh-Yechezkel, et al.
Gynecologic Oncology|September 28, 2000
Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations statusA Fishman, E Dekel, A Chetrit, et al.
JAMA|December 11, 1996
High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian CancerB Modan, E Gak, R B Sade-Bruchim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Effect of BRCA mutations on the length of survival in epithelial ovarian tumorsY Ben David, A Chetrit, G Hirsh-Yechezkel, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Cancer Chemotherapy and Pharmacology|January 1, 1991
Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridineF M Muggia, K K Chan, C Russell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1990
Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapyJ L Speyer, U Beller, N Colombo, et al.
American Journal of Human Genetics|May 1, 1997
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer familiesE Levy-Lahad, R Catane, S Eisenberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2001
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriersE Levy-Lahad, A Lahad, S Eisenberg, et al.
BJOG : an International Journal of Obstetrics and Gynaecology|July 20, 2000
p53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutationsD Yair, G Ben Baruch, A Chetrit, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 12, 2005
A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancerO Gemer, M Lurian, M Gdalevich, et al.
The New England Journal of Medicine|July 28, 2001
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutationB Modan, P Hartge, G Hirsh-Yechezkel, et al.
Gynecologic Oncology|September 28, 2000
Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations statusA Fishman, E Dekel, A Chetrit, et al.
JAMA|December 11, 1996
High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. National Israel Study of Ovarian CancerB Modan, E Gak, R B Sade-Bruchim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Effect of BRCA mutations on the length of survival in epithelial ovarian tumorsY Ben David, A Chetrit, G Hirsh-Yechezkel, et al.
Pageof 7